This is in reply to the Letter by Kahathuduwa et al. titled “Unaccounted for regression to the mean renders conclusion of article titled ‘Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin’ unsubstantiated”-Reference-Cited by-同舟云学术

This is in reply to the Letter by Kahathuduwa et al. titled “Unaccounted for regression to the mean renders conclusion of article titled ‘Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin’ unsubstantiated”

Published:2018-06-05 Issue:8 Volume:20 Page:2041-2042
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ouchi Motoshi¹,Oba Kenzo²,Suganami Hideki³^ORCID,Yoshida Akihiro⁴,Fujita Tomoe¹,Suzuki Tatsuya⁵,Yasutake Masahiro⁵⁶,Kaku Kohei⁷^ORCID

Affiliation:

1. Department of Pharmacology and Toxicology; Dokkyo Medical University School of Medicine; Tochigi Japan

2. Department of Internal Medicine; Oarai Coast Core Clinic; Ibaraki Japan

3. Clinical Data Science Department; Kowa Company, Ltd.; Tokyo Japan

4. Medical Information and Product Advancement Department; Kowa Pharmaceutical Company, Ltd; Tokyo Japan

5. Division of Geriatric Medicine, Department of General Medicine and Health Science; Nippon Medical School; Tokyo Japan

6. Department of General Medicine and Health Science; Nippon Medical School; Tokyo Japan

7. Department of General Internal Medicine; Kawasaki Medical School; Okayama Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13347/fullpdf

Reference3 articles.

1. Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin;Ouchi;Diabetes Obes Metab,2018

2. Unaccounted for regression to the mean renders conclusion of article titled “uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin” unsubstantiated;Kahathuduwa;Diabetes Obes Metab,2018

3. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials;Zhao;Diabetes Obes Metab,2018